Drugs that contain Tazemetostat Hydrobromide

1. Drug name - TAZVERIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11052093 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US8410088 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9090562 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10821113 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US9394283 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

CN107311921B EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compounds
Apr, 2032

(9 years from now)

CN104080769B EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compound
Apr, 2032

(9 years from now)

CN104080769A EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compound
Apr, 2032

(9 years from now)

CN107311921A EPIZYME INC Aryl Or Heteroaryl Substituted Benzene Compound
Apr, 2032

(9 years from now)

CN104603130B EPIZYME INC A Salt Form Of Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

CN104603130A EPIZYME INC Salt Forms Of Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

CN108358899A EPIZYME INC Human Salt Form Transmethylase Ezh2 Inhibitor Of
Apr, 2033

(10 years from now)

CN108358899B EPIZYME INC Salt Form Of Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

IN337354B EPIZYME INC Aryl-Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3486234B1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP2697199B1 EPIZYME INC Aryl-Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3150580A1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3486234A1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3150580B1 EPIZYME INC Aryl- Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP2697199A1 EPIZYME INC Aryl-Or Heteroaryl-Substituted Benzene Compounds
Apr, 2032

(9 years from now)

EP3184523A1 EPIZYME INC N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System
Apr, 2033

(10 years from now)

EP2836491A4 EPIZYME INC Salt Form Of A Human Hi Stone Methyltransf Erase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

EP2836491B1 EPIZYME INC Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

EP3184523B1 EPIZYME INC N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System
Apr, 2033

(10 years from now)

EP2836491A1 EPIZYME INC Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949999 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

US9175331 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

US8895245 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof Sep, 2031

(8 years from now)

US9334527 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

US9333217 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

US8691507 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof Sep, 2031

(8 years from now)

US10155002 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US8765732 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US9549931 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US9855275 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US10420775 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US9522152 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds Apr, 2032

(9 years from now)

US10245269 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor Apr, 2033

(10 years from now)

US9872862 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor Apr, 2033

(10 years from now)

US9688665 EPIZYME INC Methods of treating cancer Aug, 2034

(11 years from now)

US10369155 EPIZYME INC Method for treating cancer Oct, 2035

(13 years from now)

US9889138 EPIZYME INC Method for treating cancer Oct, 2035

(13 years from now)

US10786511 EPIZYME INC Method for treating cancer Dec, 2035

(13 years from now)

Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma by inhibiting enhancer of zeste homolog 2 (ezh2); method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.